SUPPLEMENTAL TABLE 4

Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined With EnteroTracker for Biliary Sampling

Bo Wen, Ying Zhang, Graeme C. Young, David Kenworthy, Adrian Pereira, Jill Pirhalla, Janine Doyle, Bethany Jordon, Joyce Zhan, and Mark Johnson

GSK, Collegeville, PA, USA (B.W., Y.Z, J.P., J.D., J.Z.) and GSK, Ware, UK (G.C.Y., D.K.) and GSK, Stevenage, UK (A.P., B.J.) and ViiV Healthcare, Durham, NC, USA (M.J.)

Journal: Drug Metab Dispos
### Supplemental Table 4. Metabolites Identified in Feces Following a Single Oral Administration of $[^{14}\text{C}]$GSK3640254 to Human at a Target Dose Level of 85 mg (Treatment Period 2)

<table>
<thead>
<tr>
<th>Peak ID</th>
<th>Metabolite structure</th>
<th>% matrix radioactivity (% dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td><img src="image" alt="Structure P" /></td>
<td>84.3 (78.5)</td>
</tr>
<tr>
<td>M4</td>
<td><img src="image" alt="Structure M4" /></td>
<td>3.3 (3.1)</td>
</tr>
<tr>
<td>M5</td>
<td><img src="image" alt="Structure M5" /></td>
<td>0.8 (0.8)</td>
</tr>
<tr>
<td>M7</td>
<td><img src="image" alt="Structure M7" /></td>
<td>0.5 (0.5)</td>
</tr>
</tbody>
</table>
M27  
Oxidation

M28b  
Oxidation

M29c  
Oxidation and N-dealkylation

Total radioactive material assigned  97.7  
% dose in matrix pool analyzed  93.1  
Total % dose excreted in matrix  93.8  

aM8 co-eluted with M13. bM9 co-eluted with M28. cM14 co-eluted with M29.